
We are pleased to announce our participation in the prestigious XXXV. Izakovič Memorial 2025, which will take place on October 8–10, 2025 at the Grandhotel Praha, Tatranská Lomnica. The Izakovič Memo...
Read moreIn the spring, we will participate in the 1st Czechoslovak Congress of Medical Genetics, which will take place from April 2–4, 2025, at the Cultural and Congress Center Elektra in the spa town of Luha...
Read moreVisit us at the 19th edition of the RANK 2025 conference, which will take place on March 19th and 20th at the Zlatá Štika Hotel in Pardubice. The conference is organized by the Czech Society of Clinic...
Read moreALKgene fusionsand ROS1 gene fusions define unique molecularsubsetsof non–small-cell lung cancer (NSCLC).EML4,KIF5B,TFG,KLC1etc., are identified as fusion partnersof ALK;SLC34A2,CD74,SDC4,EZRetc.,are identified as fusion partnersof ROS1.These fusions lead to constitutive kinase activity and activation of downstream pathways, leading to carcinogenesis.It has been reported that the presence of theALKgene fusions and ROS1gene fusionsarecorrelated with the efficacy of TKI therapy.
Detection of ALK and ROS1 fusions in patients with advanced NSCLC indicates eligibility for treatment with ALK inhibitor crizotinib.
The AmoyDx®ALK Gene Fusions and ROS1 Gene Fusions Detection Kitis an in vitronucleicacidamplification test intended for qualitative detection of 26 ALK gene fusions and 14 ROS1 gene fusions.